Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives

  • Prabhakar Semwal
  • , Sakshi Painuli
  • , Tareq Abu-Izneid
  • , Abdur Rauf
  • , Anshu Sharma
  • , Sevgi Durna Daştan
  • , Manoj Kumar
  • , Mohammed M. Alshehri
  • , Yasaman Taheri
  • , Rajib Das
  • , Saikat Mitra
  • , Talha Bin Emran
  • , Javad Sharifi-Rad
  • , Daniela Calina
  • , William C. Cho
  • Graphic Era
  • Al Ain University of Science and Technology
  • University of Swabi
  • Dr. Yashwant Singh Parmar University of Horticulture and Forestry
  • Cumhuriyet University
  • ICAR - Central Institute of Research on Cotton Technology
  • Ministry of National Guard-Health Affairs
  • Shahid Beheshti University of Medical Sciences
  • University of Dhaka
  • BGC Trust University Bangladesh
  • Daffodil International University
  • Universidad del Azuay
  • Craiova University of Medicine and Pharmacy
  • Queen Elizabeth Hospital Hong Kong

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

185 Citas (Scopus)

Resumen

Plants including Rhizoma polgonati, Smilax china, and Trigonella foenum-graecum contain a lot of diosgenin, a steroidal sapogenin. This bioactive phytochemical has shown high potential and interest in the treatment of various disorders such as cancer, diabetes, arthritis, asthma, and cardiovascular disease, in addition to being an important starting material for the preparation of several steroidal drugs in the pharmaceutical industry. This review aims to provide an overview of the in vitro, in vivo, and clinical studies reporting the diosgenin's pharmacological effects and to discuss the safety issues. Preclinical studies have shown promising effects on cancer, neuroprotection, atherosclerosis, asthma, bone health, and other pathologies. Clinical investigations have demonstrated diosgenin's nontoxic nature and promising benefits on cognitive function and menopause. However, further well-designed clinical trials are needed to address the other effects seen in preclinical studies, as well as a better knowledge of the diosgenin's safety profile.

Idioma originalInglés
Número de artículo1035441
PublicaciónOxidative Medicine and Cellular Longevity
Volumen2022
DOI
EstadoPublicada - 2022
Publicado de forma externaSí

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

  1. ODS 3: Salud y bienestar
    ODS 3: Salud y bienestar

Huella

Profundice en los temas de investigación de 'Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives'. En conjunto forman una huella única.

Citar esto